Nightingale Health Announces Strategic Partnership with Kirin and Mitsui to Bring Nightingale’s Internationally Recognised Blood-Testing Services to the Japanese Market

Kirin Holdings Company, Limited, Mitsui & Co., Ltd., and Nightingale Health Ltd., a market leader in advanced blood-testing for preventative health solutions, today announce a strategic partnership to launch Nightingale’s blood-testing services in Japan, as well as to develop novel wellness products. The aim of this initiative is to help people to stay healthy by leveraging the globally unique biomarker information provided by Nightingale’s blood-test. As part of the strategic partnership, Kirin and Mitsui have made a minor equity investment to Nightingale.

“Our blood-test has been used by the global leaders in medical science for years. Several scientific flagship studies have validated that Nightingale’s blood-test offers unprecedented insights into health and chronic diseases,” said Nightingale Health’s CEO Teemu Suna. ”We think that people should have direct access to preventative next-generation health technologies – this is why our mission at Nightingale is to make our blood-test conveniently available globally to benefit everyone’s health”.

Over the past 5 years, Nightingale’s blood-testing technology has been used to publish more than 200 peer- reviewed scientific articles in the world’s leading biomedical journals and the technology has been approved by the regulatory authorities in Europe for healthcare use. Nightingale has perfected its blood- test to start a new era of preventative health services in chronic diseases and the global roll-out of its technology is set to launch later this year. Mitsui’s and Kirin’s unique experience in developing international markets and innovative products, respectively, will accelerate Nightingale’s efforts to make next-generation blood-testing directly accessible in consumer markets.

“We are pleased to announce this strategic partnership with Nightingale to bring preventative health and wellness solutions together with our partner company Kirin,” said Toshitaka Inuzuka, General Manager, NutriScience Division, Mitsui. “We will start our collaboration by bringing Nightingale’s disruptive blood- test technology to the Japanese market as the initial stage, accelerating our efforts in this space.”

“I believe Nightingale’s blood-test provides very valuable biomarker information about health in chronic diseases. When integrating the biomarkers with multiple health-related data sources and machine learning, we will have crucial knowledge to develop new nutritional products,” said Toru Yoshimura, Senior Executive Officer, Kirin Holdings. “This strategic partnership with Nightingale and Mitsui reinforces our key initiative to establish and foster new businesses bridging Pharmaceuticals and Food & Beverages especially in providing personalized solutions in the wellness area.”

About Nightingale Health

Nightingale Health is a fast-growing global health tech company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. With our pioneering blood-testing services, we provide deep health insights and can measure the effects of lifestyle interventions that are invisible in standard lab tests. The deep knowledge fuels scientific discoveries, industry developments, and encourages people to make positive lifestyle changes that take their health forward. For more information, visit http://www.nightingalehealth.com

About Kirin

Kirin is a global, multi-industry food and beverages company headquartered in Tokyo. Kirin manufactures and sells alcohol and non-alcohol beverages globally through its underlying companies such as Kirin Brewery (Japan), Kirin Beverage (Japan), Lion (Australia), and Myanmar Brewery (Myanmar), as well as engages in pharmaceutical and bio-chemical businesses through Kyowa Kirin and Kyowa Hakko Bio. Under the long-term management vision “Kirin Group Vision 2027”, Kirin aims to become a global leader in CSV, creating value in domains ranging from food and beverages to pharmaceuticals. For more information, visit https://www.kirinholdings.co.jp/english.

About Mitsui

Mitsui is one of the most diversified and comprehensive trading, investment and service enterprises in the world, with 139 offices in 66 countries as of Apr, 2019. Utilizing its global operating locations, network and information resources, Mitsui is multilaterally pursuing business that ranges from product sales, worldwide logistics and financing, through to the development of major international infrastructure and other projects in the following fields: Iron & Steel Products, Mineral & Metal Resources, Infrastructure Projects, Mobility, Chemicals, Energy, Food, Food & Retail Management, Healthcare & Service, IT & Communication Business, Corporate Development Business. Mitsui is actively taking on challenges for global business innovation around the world. For more information, visit http://www.mitsui.com.


For more details contact:

Teemu Suna
CEO, Founder
Nightingale Health Ltd. Helsinki, Finland
Tel. +358 40 196 1669

press@nightingalehealth.com
 

About Us

Nightingale Health is a fast-growing global health tech company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. With our pioneering blood-testing services, we provide deep health insights and can measure the effects of lifestyle interventions that are invisible in standard lab tests. The deep knowledge fuels scientific discoveries, industry developments, and encourages people to make positive lifestyle changes that take their health forward.

Subscribe

Media

Media

Quick facts

Kirin Holdings Company, Limited, Mitsui & Co., Ltd., and Nightingale Health Ltd., a market leader in advanced blood-testing for preventative health solutions, today announce a strategic partnership to launch Nightingale’s blood-testing services in Japan, as well as to develop novel wellness products.
Tweet this
The aim of this initiative is to help people to stay healthy by leveraging the globally unique biomarker information provided by Nightingale’s blood-test.
Tweet this
As part of the strategic partnership, Kirin and Mitsui have made a minor equity investment to Nightingale.
Tweet this

Quotes

We are pleased to announce this strategic partnership with Nightingale to bring preventative health and wellness solutions together with our partner company Kirin
Toshitaka Inuzuka, General Manager, NutriScience Division, Mitsui
I believe Nightingale’s blood-test provides very valuable biomarker information about health in chronic diseases. When integrating the biomarkers with multiple health-related data sources and machine learning, we will have crucial knowledge to develop new nutritional products
Toru Yoshimura, Senior Executive Officer, Kirin Holdings